GMP-Compliant Production of Human Placenta-Derived Mesenchymal Stem Cells.
Hamid Reza AghayanMoloud PayabFereshteh Mohamadi-JahaniSeyed Sajjad AghayanBagher LarijaniBabak ArjmandPublished in: Methods in molecular biology (Clifton, N.J.) (2021)
Mesenchymal stem cells are one of the most attractive sources for stem cell research and therapy. Their safety and efficacy have been demonstrated in many clinical trials. Because of their low immunogenicity and immunomodulatory properties, allogenic MSCs have been transplanted in different clinical studies. MSCs could be in different adult- and fetal-derived tissues including pregnancy products. Placenta-derived mesenchymal stem cells (PLMSCs) that can be harvested without using any invasive procedures from a discarding tissue are one of the important types of mesenchymal stem cells for therapeutic applications. Stem cell manufacturing for therapeutic applications should be in compliance with the basic principles of good manufacturing practice (GMP). Herein, the current chapter is to describe GMP-compliant production of human PLMSCs, which are suitable for clinical applications.
Keyphrases
- mesenchymal stem cells
- stem cells
- umbilical cord
- endothelial cells
- clinical trial
- cell therapy
- bone marrow
- biofilm formation
- induced pluripotent stem cells
- pluripotent stem cells
- gene expression
- healthcare
- primary care
- drinking water
- randomized controlled trial
- preterm birth
- pregnant women
- young adults
- pseudomonas aeruginosa
- open label
- pregnancy outcomes